Evaxion Biotech A/S - Understand $evax stock

$EVAX Market Cap: $7.738 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$278.0K

TTM

Gross Margin

Net Earnings

-$15.21M

TTM

Current Assets

$10.70M

Q2 2024

Current Liabilities

$3.821M

Q2 2024

Current Ratio

280.03%

Q2 2024

Total Assets

$15.23M

Q2 2024

Total Liabilities

$13.98M

Q2 2024

Book Value

$1.253M

Q2 2024

Cash

P/E

-0.5087

Nov 29, 2024 EST

Free Cash Flow

-$26.77M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018
Revenue	$73.00K	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018
Revenue	$73.00K	$0.00	$0.00	$0.00	$0.00	$0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018
Selling, General & Admin	$10.08M	$8.066M	$6.180M	$5.650M	$2.630M	$1.880M
YoY Change	24.96%	30.52%	9.38%	114.83%	39.89%
% of Gross Profit
Research & Development	$11.58M	$17.06M	$19.61M	$11.61M	$8.650M	$3.670M
YoY Change	-32.13%	-13.02%	68.91%	34.22%	135.69%
% of Gross Profit
Depreciation & Amortization	$615.0K	$571.0K	$344.0K	$110.0K	$80.00K	$70.00K
YoY Change	7.71%	65.99%	212.73%	37.5%	14.29%
% of Gross Profit
Operating Expenses	$22.27M	$17.06M	$25.83M	$16.57M	$10.86M	$5.630M
YoY Change	30.57%	-33.98%	55.91%	52.58%	92.9%
Operating Profit
YoY Change

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018
Interest Expense	-$718.0K	$34.00K	$1.124M	-$10.00K	-$1.160M	-$640.0K
YoY Change	-2211.76%	-96.98%	-11340.0%	-99.14%	81.25%
% of Operating Profit
Other Income/Expense, Net
YoY Change

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018
Pretax Income	-$22.92M	-$23.94M	-$24.71M	-$16.58M	-$12.02M	-$6.270M
YoY Change	-4.29%	-3.11%	49.03%	37.94%	91.71%
Income Tax	-$790.0K	-$772.0K	-$178.0K	-$1.560M	-$830.0K	-$740.0K
% Of Pretax Income
Net Earnings	-$22.13M	-$23.17M	-$24.53M	-$15.02M	-$11.20M	-$5.540M
YoY Change	-4.51%	-5.56%	63.33%	34.11%	102.17%
Net Earnings / Revenue	-30308.22%
Basic Earnings Per Share
Diluted Earnings Per Share	-$8.09	-$0.98	-$1.260M	-$792.6K	-$591.0K	-$292.3K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018
Cash & Short-Term Investments	$5.583M	$13.18M	$32.17M	$5.830M	$9.560M	$7.430M
YoY Change	-57.65%	-59.01%	451.73%	-39.02%	28.67%
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets	$1.701M	$2.715M	$1.201M	$2.910M	$450.0K	$150.0K
YoY Change	-37.35%	126.06%	-58.73%	546.67%	200.0%
Inventory
Prepaid Expenses
Receivables				$420.0K	$20.00K	$30.00K
Other Receivables				$1.790M	$930.0K	$770.0K
Total Short-Term Assets	$8.350M	$16.99M	$34.71M	$10.95M	$10.96M	$8.380M
YoY Change	-50.84%	-51.06%	216.94%	-0.09%	30.79%
Property, Plant & Equipment	$4.343M	$4.675M	$5.174M	$460.0K	$130.0K	$130.0K
YoY Change	-7.1%	-9.64%	1024.78%	253.85%	0.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$167.0K	$156.0K	$191.0K	$260.0K	$30.00K	$20.00K
YoY Change	7.05%	-18.32%	-26.54%	766.67%	50.0%
Total Long-Term Assets	$4.539M	$5.040M	$5.458M	$1.020M	$120.0K	$130.0K
YoY Change	-9.94%	-7.66%	435.1%	750.0%	-7.69%
Total Assets	$12.89M	$22.03M	$40.16M	$11.97M	$11.08M	$8.510M
YoY Change
Accounts Payable	$2.689M	$2.085M	$2.848M	$2.650M	$650.0K	$140.0K
YoY Change	28.97%	-26.79%	7.47%	307.69%	364.29%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$485.0K	$439.0K	$440.0K	$20.00K	$40.00K	$8.640M
YoY Change	10.48%	-0.23%	2100.0%	-50.0%	-99.54%
Total Short-Term Liabilities	$7.084M	$3.762M	$4.323M	$4.930M	$1.720M	$9.420M
YoY Change	88.3%	-12.98%	-12.31%	186.63%	-81.74%
Long-Term Debt	$10.39M	$9.816M	$3.250M	$0.00	$0.00	$20.00K
YoY Change	5.8%	202.03%			-100.0%
Other Long-Term Liabilities	$149.0K	$144.0K	$153.0K
YoY Change	3.47%	-5.88%
Total Long-Term Liabilities	$10.53M	$9.960M	$3.403M	$0.00	$0.00	$20.00K
YoY Change	5.76%	192.68%			-100.0%
Total Liabilities	$17.62M	$13.72M	$7.726M	$4.930M	$1.720M	$9.440M
YoY Change	28.39%	77.61%	56.71%	186.63%	-81.78%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019	2018
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $7.7378 Million

About Evaxion Biotech A/S

Evaxion Biotech A/S engages in the discovery and development of immunotherapies for cancer and infectious diseases. The firm decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.

Industry: Biological Products, (No Diagnostic Substances) Peers: Forward Pharma A/S Galecto, Inc. IO Biotech, Inc.